Rejuvenate Bio

6 articles about Rejuvenate Bio

• Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis

  2/14/2024

  Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the treatment of canine osteoarthritis (OA), a complex chronic disease that affects dogs’ mobility and overall quality of life.

• 

  Biopharma Targets the Untapped Potential of the Human Healthspan

  5/22/2023

  More than $5 billion poured into the longevity space in 2022, and experts say the science is now primed to make a real difference in extending human healthspan.

• Rejuvenate Bio Announces Data for Gene Therapy RJB-01 in Mitral Valve Disease at 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)

  5/18/2023

  Rejuvenate Bio, announced new data for its gene therapy RJB-01 from a pilot study in canines with myxomatous mitral valve disease, at the 26th Annual Meeting of the American Society of Gene and Cell Therapy, held May 16-20, 2023, in Los Angeles, California.

• Rejuvenate Bio Announces New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal

  1/9/2023

  Rejuvenate Bio, today announced new preclinical research published to the preprint server bioRxiv, that evaluates how partial reprogramming could be a potential treatment in the elderly to reverse age-associated diseases and potentially extend human lifespan.

• Rejuvenate Bio Appoints Deborah Ascheim, M.D., as Chief Medical Officer

  1/3/2023

  Rejuvenate Bio, today announced the appointment of Deborah Ascheim, M.D., as Chief Medical Officer.

• Rejuvenate Bio Announces Expansion of Scientific Advisory Board

  10/3/2022

  Rejuvenate Bio today announced the appointments of Hugh Calkins, M.D., Stephen Chelko, Ph.D., and Dr. Elif Oral, M.D., to its Scientific Advisory Board (SAB).